Tirzepatide Reduces Liver Fibrosis in 190-Patient NASH Trial

Tirzepatide significantly reduced liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (NASH) over 52 weeks, according to a phase 2 trial published in The New England Journal of Medicine. The study of 190 patients found that 51% of those receiving the highest dose achieved fibrosis improvement of at least one stage compared to 30% on placebo (p=0.02).

The NEJM study represents one of the first major trials showing a GLP-1 receptor agonist can meaningfully improve liver scarring in NASH patients. Researchers enrolled patients with biopsy-confirmed NASH and significant fibrosis, randomly assigning them to receive weekly injections of tirzepatide at 5mg, 10mg, or 15mg doses versus placebo for one year.

Patients receiving the 15mg dose showed the strongest results, with 62% achieving resolution of steatohepatitis without worsening fibrosis compared to 31% on placebo (p=0.006). The drug also produced substantial weight loss, with the highest dose group losing an average of 15.7% of body weight versus 1.2% for placebo.

Tirzepatide, marketed as Mounjaro and Zepbound, works by activating both GLP-1 and GIP hormone receptors to regulate blood sugar, slow gastric emptying, and reduce appetite. These mechanisms appear to have beneficial downstream effects on liver metabolism and inflammation.

NASH affects an estimated 6% of U.S. adults and is closely linked to obesity and type 2 diabetes — conditions that tirzepatide already treats. The liver disease occurs when fat accumulates in the liver, triggering inflammation that over time leads to dangerous scarring. Without intervention, NASH can progress to cirrhosis, liver failure, and hepatocellular carcinoma.

The trial's primary endpoint measured histologic improvement in liver biopsies using standardized scoring systems. Secondary endpoints included changes in liver enzyme levels, body weight, and metabolic parameters. Most patients tolerated the medication well, with gastrointestinal side effects being the most common reason for discontinuation.

Eli Lilly, which manufactures tirzepatide, is likely to pursue FDA approval for NASH treatment based on these phase 2 results. The company would need to conduct larger phase 3 trials to confirm the findings before seeking regulatory approval for this new indication.

The research adds to evidence that GLP-1-based medications offer benefits across multiple organ systems. Previous studies have suggested cardiovascular and kidney protective effects, positioning these drugs as comprehensive treatments for metabolic disease.

For patients currently taking tirzepatide for diabetes or weight management, the liver benefits represent a potential additional therapeutic effect. However, physicians emphasize that patients shouldn't start the medication solely for liver protection without discussing the drug's significant cost, insurance coverage limitations, and potential gastrointestinal side effects with their healthcare provider.